Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Retained Earnings: 2013-2024

Historic Retained Earnings for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $568.8 million.

  • Amphastar Pharmaceuticals' Retained Earnings rose 21.03% to $642.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.5 million, marking a year-over-year increase of 21.03%. This contributed to the annual value of $568.8 million for FY2024, which is 38.98% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Retained Earnings stood at $568.8 million for FY2024, which was up 38.98% from $409.3 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Retained Earnings ranged from a high of $568.8 million in FY2024 and a low of $117.8 million during FY2020.
  • Moreover, its 3-year median value for Retained Earnings was $409.3 million (2023), whereas its average is $416.6 million.
  • Data for Amphastar Pharmaceuticals' Retained Earnings shows a peak YoY skyrocketed of 53.12% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Retained Earnings stood at $117.8 million in 2020, then soared by 53.12% to $180.3 million in 2021, then spiked by 50.68% to $271.7 million in 2022, then surged by 50.62% to $409.3 million in 2023, then surged by 38.98% to $568.8 million in 2024.